Cambrex Corporation has opened a new 120 sqm quality control (QC) laboratory at its site in Paullo, Milan, Italy. The laboratory expands on the current QC facilities that analyse and test its generic API portfolio of products during development and manufacturing.
The additional laboratory space will increase the efficiency of the QC department as the site expands the number of generic APIs in development and is now fully operational, having been authorised by the Agenzia Italiana Del Farmaco (AIFA).
New instruments, including a polarimeter and infrared spectrometer, have been added, with the systems linked to secure, electronic data capturing software to allow full traceability in line with regulatory requirements.
This addition to the site builds on the small molecule company’s US$3 million investment in API manufacturing capabilities in the site announced in October last year. The latest in a sequence of updates and upgrades to the site over the last few years
Aldo Magnini, Managing Director of Cambrex Milan, said: “Our facility in Milan is the centre of the Cambrex’s generic API business, and this investment is the latest in a number of steps we have taken at the site to increase its efficiency and flexibility as we look to grow the portfolio of products that we offer,”
Cambrex manufactures over 70 generic APIs which are produced to cGMP standards at the Milan site, where seven production departments are supported by a pilot plant, kilo scale plant and development and analytical laboratories.